DNMT3A and acute myeloid leukemia: With a median follow-up of 43.9 months (range 0.1–250.7 months), patients with DNMT3A mutations had a higher risk to transform to AML (5-year AML transformation rate, 34.4 versus 22.5%, P = 0.013; Fig. 2).